Biological Products, (No Diagnostic Substances) · CERRITOS, CA, United States
$0.11
-2.48% (-$0.00)2026-07-20
Smart-Money SignalNeutral · 54/100— Insider open-market flow is flat over 90 days
Price Performance
Historical data including institutional events
Company Profile
C
Chris Kim
CEO & Executive Director
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States.
It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
The company was founded in 2018 and is based in Cerritos, California.
